Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats

被引:28
作者
Ferron, GM [1 ]
McKeand, W [1 ]
Mayer, PR [1 ]
机构
[1] Wyeth Ayerst Res, Clin Pharmacokinet, Radnor, PA 19087 USA
关键词
D O I
10.1177/00912700122009953
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The relationship between the pharmacokinetics of pantoprazole, an irreversible proton pump inhibitor, and ifs effect on gastric acid secretion was evaluated in humans and rats. Pantoprazole pharmacokinetics were studied in 6 rats (5 mg/kg, N) and 22 healthy volunteers (10 to 80 mg, N and oral). Gastric acid secretion under maximum pentagastrin stimulation was measured after IV administration of placebo or pantoprazole in 31 rats (0.12 to 1.15 mg/kg) for 8 hours and in 32 subjects (20 to 120 mg) for 24 hours. Pantoprazole has short half-lives of 0.5 hours in rats and 0.8 hours in humans. After administration of the highest dose, acid secretion was fully inhibited within 1: hour and for the whole observation period in both species. An irreversible pharmacodynamic response model was successfully developed and validated. The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h(-1) and 0.031 h(-1), respectively. The maximum inhibition and the overall effect of pantoprazole are related to exposure, and the onset is related to initial pantoprazole concentrations. It was concluded that this irreversible response model accurately describes the effect of N and oral pantoprazole on gastric secretion and may be used to predict effects under other dosage regimens. (C) 2001 the American College of Clinical Pharmacology.
引用
收藏
页码:149 / 156
页数:8
相关论文
共 14 条
[1]  
BENET LZ, 1994, ALIMENT PHARM THERAP, V8, P25
[2]  
BLIESATH H, 1992, INT J CLIN PHARM TH, V30, P439
[3]   Pantoprazole - A review of its pharmacological properties and therapeutic use in acid-related disorders [J].
Fitton, A ;
Wiseman, L .
DRUGS, 1996, 51 (03) :460-482
[4]   CIMETIDINE PLASMA CONCENTRATION-RESPONSE RELATIONSHIPS [J].
GUGLER, R ;
FUCHS, G ;
DIECKMANN, M ;
SOMOGYI, AA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (06) :744-748
[5]  
Huber R, 1996, INT J CLIN PHARM TH, V34, P185
[6]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF THE H+/K+ ATPASE INHIBITOR (BY-1023/SK+F96022) AND ITS SULFONE METABOLITE IN SERUM OR PLASMA BY DIRECT INJECTION AND FULLY AUTOMATED PRECOLUMN SAMPLE CLEANUP [J].
HUBER, R ;
MULLER, W ;
BANKS, MC ;
ROGERS, SJ ;
NORWOOD, PC ;
DOYLE, E .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 529 (02) :389-401
[8]  
KATASHIMA M, 1995, DRUG METAB DISPOS, V23, P718
[9]   Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans [J].
Katashima, M ;
Yamamoto, K ;
Tokuma, Y ;
Hata, T ;
Sawada, Y ;
Iga, T .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1998, 23 (01) :19-26
[10]   Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: A dose-response study [J].
Pisegna, JR ;
Martin, P ;
McKeand, W ;
Ohning, G ;
Walsh, JH ;
Paul, J .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (10) :2874-2880